Long-Acting IGF-1 Variant Research Compound · WADA Prohibited 20–30× longer half-life than base IGF-1

IGF-1 LR3

Long Arg3 IGF-1 · R3-IGF-1 · Increlex variant · Long-Acting IGF-1

"IGF-1 with an Arg3 substitution and N-terminal extension that prevents IGFBP binding — extending half-life from minutes to 20–30 hours and enabling full-body systemic IGF-1 activity rather than hepatic clearance. The most widely used IGF-1 variant in the bodybuilding community for muscle hypertrophy, fat loss, and recovery. A completely different pharmacokinetic profile to base IGF-1."

Half-life
20–30 hours vs ~minutes for base IGF-1
Key difference
Reduced IGFBP binding → longer free IGF-1 window
Use
Muscle hypertrophy · fat loss · recovery
FDA Status
Not approved · research compound only
WADA
Prohibited at all times
Origin & Background

The IGF-1 the community actually uses

Base IGF-1 (insulin-like growth factor 1) has an almost comically short half-life in circulation — typically 5–10 minutes as a free peptide before it is either bound by one of six IGF-binding proteins (IGFBPs) or cleared by the liver. This renders direct IGF-1 injection impractical for most bodybuilding and performance applications: the window of activity is so brief that site injections near target tissue are required, and even then the systemic exposure is minimal. This is why the IGF-1 in GH protocols works via the sustained hepatic production stimulated by GH — not via the brief free IGF-1 pulse itself.

IGF-1 LR3 (Long Arg3 IGF-1) solves this problem through two modifications: (1) an Arg3 substitution at position 3 of the mature IGF-1 sequence, which significantly reduces binding to IGFBP-3 (the principal binding protein that sequesters circulating IGF-1), and (2) a 13-amino-acid N-terminal extension peptide. Together these modifications extend half-life to 20–30 hours and enable the peptide to circulate freely in systemic blood rather than being immediately sequestered or cleared. The result: one daily or alternate-day injection produces sustained, whole-body IGF-1 receptor activation rather than a brief localised stimulus.

IGF-1 LR3 was originally developed for research purposes — including studying IGF-1 biology without the confound of rapid clearance. Its adoption by the bodybuilding community predates most other research peptides and reflects the community's early recognition that the pharmacokinetics, not the receptor binding, were the limiting factor in using IGF-1 therapeutically.

Why this is a fundamentally different compound to base IGF-1: When you read IGF-1 research using native IGF-1, the pharmacokinetics are completely different. LR3 produces 20–30 hours of free IGF-1 receptor stimulation from a single injection. Base IGF-1 produces minutes. Every clinical application, every dose-response relationship, every safety consideration differs between the two. The entry for IGF-1 in this book covers the receptor biology and physiology; this entry covers the distinct pharmacology of LR3 specifically.

Science & Mechanism

IGFBP evasion — 20–30 hours of free IGF-1 activity

Mechanism of Action

1
Reduced IGFBP-3 binding: The Arg3 substitution reduces affinity for IGFBP-3, the principal binding protein that sequesters ~80% of circulating IGF-1 in a ternary complex with ALS (acid-labile subunit). By evading this binding, LR3 circulates as free peptide rather than bound reservoir — maintaining receptor-accessible concentrations for 20–30 hours post-injection.
2
IGF-1R activation (same receptor): IGF-1 LR3 binds the same IGF-1 receptor (IGF-1R) as native IGF-1 with comparable affinity. IGF-1R is a receptor tyrosine kinase — binding triggers autophosphorylation → IRS-1 → PI3K/Akt (hypertrophy, survival, glucose uptake) and MAPK/ERK (proliferation, differentiation) pathways. The hypertrophy signal is potent and operates in skeletal muscle, cardiac muscle, and virtually every other tissue.
3
Systemic vs local delivery: Because LR3 circulates systemically for 20–30 hours, it stimulates IGF-1R throughout the body — skeletal muscle, connective tissue, bone, and organs simultaneously. Base IGF-1 injected locally acts primarily at the injection site before being cleared. LR3 produces a more anabolic whole-body environment but also activates IGF-1R in all tissues, including any with elevated proliferative potential.
4
Glucose transport and partitioning: IGF-1R activation stimulates GLUT4 translocation and glucose uptake in muscle independently of insulin. LR3's 20–30 hour activity window produces sustained insulin-like glucose partitioning into muscle — lowering blood glucose and directing carbohydrate calories toward glycogen synthesis and lean tissue. This effect is dose-dependent and can cause hypoglycaemia at higher doses.
5
Satellite cell activation: IGF-1 is the principal driver of skeletal muscle satellite cell activation — the muscle stem cells that fuse with fibres to enable true hypertrophy beyond myofibrillar volume changes. LR3's prolonged systemic exposure maximises satellite cell signalling, potentially enabling more structural muscle growth than brief-acting IGF-1 preparations.
Community Voices

What people report

Advanced User ReportResearch compound use — significant experience required

"50mcg LR3 immediately post-workout on training days, 20 weeks. The muscle fullness and recovery speed change is noticeable within 2 weeks. Strength gains are modest — this isn't a strength compound. The visual change in muscle density and the recovery speed improvement are the main effects I used it for."

Male, 29, competitive physique athlete. Post-workout timing is the dominant community protocol — the theory being that exercise-induced IGF-1R upregulation in the trained muscle amplifies LR3's effect in those specific fibres during the post-workout anabolic window.

Blood Glucose WarningCommunity safety report

"Learned the hard way — took 100mcg before bed without eating. Woke up sweating and confused at 3am. Blood glucose was 52 mg/dL. LR3 drives glucose into muscle aggressively. Always eat carbohydrates with or immediately after administration."

Male, 32. Hypoglycaemia is the most serious practical risk with LR3 — it is not rare at doses above 50mcg, especially in fasted or low-carbohydrate states. The community rule is non-negotiable: always have fast-acting carbohydrates on hand and never administer fasted at night.

Safety First

Risks — hypoglycaemia is real

🚨
Hypoglycaemia at higher doses is a genuine emergency risk. Always have fast-acting carbohydrates available. Never administer fasted at high doses. The 20–30 hour glucose-partitioning activity means blood glucose can drop significantly, particularly overnight. This is the most dangerous acute risk with LR3.
Serious
Hypoglycaemia — dose-dependent glucose-partitioning into muscle can cause symptomatic hypoglycaemia. Highest risk: fasted administration, high doses (>80mcg), overnight. Always eat 30–50g carbohydrates with or immediately after injection. Keep glucose tablets or fast-acting sugar accessible. Monitor blood glucose if using above 50mcg.
Serious
Insulin-like interactions — do not combine with insulin without precise glucose monitoring. Additive hypoglycaemia risk is extremely dangerous. IGF-1 LR3 and insulin should not be used together without expert supervision and continuous glucose monitoring.
Moderate
Proliferative risk (long-term) — systemic IGF-1R activation at supraphysiological levels for extended periods stimulates cellular proliferation broadly. The theoretical cancer promotion risk — well-documented in epidemiological studies linking chronically elevated IGF-1 to cancer incidence — is amplified by LR3's 20–30 hour systemic activity. Cycle length should be limited; anyone with a personal or family cancer history should not use LR3.
Moderate
Organ and tissue growth — IGF-1R is expressed in all tissues. Prolonged supraphysiological exposure can increase organ size (gut hypertrophy, cardiac hypertrophy at very high doses). Gut hypertrophy from prolonged IGF-1 excess is the "GH gut" phenomenon familiar to the bodybuilding community.
Honest Assessment

Editor's summary

IGF-1 LR3 is genuinely one of the most potent body composition compounds available — the pharmacokinetic engineering that created it was elegant and effective. The 20–30 hour free IGF-1 window is a fundamentally different proposition to base IGF-1. The community evidence for muscle density, recovery speed, and body composition is consistent over decades of use.

It is also one of the most pharmacologically serious compounds in this book. The hypoglycaemia risk is acute and real. The proliferative risk over long cycles is theoretical but not negligible — IGF-1 and cancer risk epidemiology is well-established. This is a compound for experienced users who understand glucose management, cycle length, and the importance of not stacking with insulin without intensive monitoring. It is not an entry-level peptide.

Verdict
"The most pharmacologically potent muscle hypertrophy peptide in the book. 20–30 hour free IGF-1 activity. Real body composition effects. Real hypoglycaemia risk — have carbohydrates available always. Proliferative risk limits cycle length. Experienced users only. Not a beginner compound."